Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

NCT07405086 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Advanced Biliary Tract Carcinoma
Advanced Head and Neck Squamous Cell Carcinoma
Advanced Hepatocellular Carcinoma
Advanced Lung Non-Small Cell Carcinoma
Advanced Malignant Solid Neoplasm
Advanced Melanoma
Advanced Renal Cell Carcinoma
Metastatic Biliary Tract Carcinoma
Metastatic Head and Neck Squamous Cell Carcinoma
Metastatic Hepatocellular Carcinoma
Metastatic Lung Non-Small Cell Carcinoma
Metastatic Malignant Solid Neoplasm
Metastatic Melanoma
Metastatic Renal Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Stage III Hepatocellular Carcinoma AJCC v8
Stage III Lung Cancer AJCC v8
Stage III Renal Cell Cancer AJCC v8
Stage IV Hepatocellular Carcinoma AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IV Renal Cell Cancer AJCC v8

Interventions

PROCEDURE: Biospecimen Collection
DRUG: Immune Checkpoint Inhibitor

Sponsor

OHSU Knight Cancer Institute

Collaborators

Oregon Health and Science University